We are live on
!
Find out more
SCM
Spyglass Capital Management Portfolio holdings
AUM
$1.41B
1-Year Est. Return
7.96%
This Fund
S&P 500
This Quarter
Est. Return
+24.03%
1 Year Est. Return
+7.96%
3 Year Est. Return
+119.41%
5 Year Est. Return
+57.27%
10 Year Est. Return
–
AUM
$1.78B
AUM Growth
+$255M
(+17%)
Cap. Flow
-$33.9M
Cap. Flow
% of AUM
-1.91%
Top 10 Holdings %
Top 10 Hldgs %
51.13%
Holding
27
New
2
Increased
15
Reduced
8
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Illumina
ILMN
|
+$76.6M |
| 2 |
Medpace
MEDP
|
+$41M |
| 3 |
CYBR
CyberArk
CYBR
|
+$35.3M |
| 4 |
CoStar Group
CSGP
|
+$29.6M |
| 5 |
WillScot Mobile Mini Holdings
WSC
|
+$19.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Applovin
APP
|
+$127M |
| 2 |
Ascendis Pharma A/S
ASND
|
+$97.5M |
| 3 |
Affirm
AFRM
|
+$35.9M |
| 4 |
TransDigm Group
TDG
|
+$34.8M |
| 5 |
Astera Labs
ALAB
|
+$26.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.17% |
| 2 | Consumer Discretionary | 19.88% |
| 3 | Healthcare | 17.45% |
| 4 | Financials | 8.97% |
| 5 | Communication Services | 7.98% |
Similar funds
EWS
KC
CBA
PTC
EA
IAS
BC
TWM
Spyglass Capital Management's Q4 2024 Portfolio in Review
As of Q4 2024, Spyglass Capital Management held 27 positions worth $1.78B, up 17% from $1.52B the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Spyglass Capital Management's Q4 2024 filing shows 2 new, 15 increased, 8 reduced and 2 closed positions. Its largest new stake was Illumina: 537,716 shares worth $71.9M. The largest sale was Applovin, an estimated $127M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 29% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- Spyglass Capital Management's largest Q4 2024 buy was Illumina: 537,716 shares worth $71.9M.
- Spyglass Capital Management added most to Medpace in Q4 2024, an estimated $41M increase.
- Spyglass Capital Management's biggest Q4 2024 reduction was Applovin, cutting an estimated $127M.
- Spyglass Capital Management fully exited Ascendis Pharma A/S in Q4 2024, selling an estimated $97.5M.
- Spyglass Capital Management's ten largest holdings make up 51% of its $1.78B portfolio in Q4 2024.
- Spyglass Capital Management opened 2 new positions and closed 2 in Q4 2024.
- Spyglass Capital Management's portfolio value rose 17% quarter-over-quarter to $1.78B.
Based on Spyglass Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.